Tuesday, January 20, 2026

Focus Vitamins Launches Preservative-Free Drops for Dry Eye

The preservative-free eye drops are available in single-dose vials. 

Tuesday, January 20, 2026

Japan Advances Regulatory Review of MCO-010

Sakigake and Orphan Drug designations granted; FDA has conditionally approved the Mogenry brand name.

Tuesday, January 20, 2026

Ocugen Reports Positive Phase 2 Data From OCU410 Gene Therapy for GA

Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs control

Tuesday, January 20, 2026

Generic Equivalent of Extra-Strength Pataday Once Daily Relief Now Available

Dr. Reddy’s olopatadine hydrochloride ophthalmic solution USP, 0.7% is an antihistamine eye drop, indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander, the company said.

Friday, January 16, 2026

TheraTears Expands Dry Eye Portfolio With Eyelid Cleansing Wipes, Drops

TheraTears announced 2 new additions to its portfolio launching nationwide in February 2026: TheraTears Eyelid Cleansing Wipes and TheraTears Dry & Tired Preservative Free Lubricant Eye Drops.

Wednesday, January 14, 2026

FDA Clears Rayner's Sophi Phaco System

The company said that surgeons and clinical teams can benefit from faster setup, quicker patient turnover, and greater mobility.

Tuesday, January 13, 2026

RevitalVision Demonstrates Efficacy, Safety in Infantile Nystagmus

Positive clinical data shows improvement in visual function in patients with infantile nystagmus

Tuesday, January 13, 2026

Topcon, RemoniHealth Partner to Advance Remote Monitoring and Care Continuity

The strategic partnership expands Topcon's home monitoring and connected-care vision by combining its imaging, AI analytics, and interoperable platforms with RemoniHealth’s remote-monitoring technology.

Tuesday, January 13, 2026

Conexiant Announces 30th Anniversary of Ophthalmology Management

For 3 decades, OM has delivered authoritative coverage of clinical advancements, innovations in surgical technique, regulatory and reimbursement changes, and best practices for efficiency and leadership.

Thursday, January 8, 2026

Ollin Biosciences Reports Positive Results for VEGF/Ang2 Bispecific Antibody

The next-generation VEGF/Ang2 bispecific antibody demonstrates rapid retinal drying and vision gains in patients with diabetic macular edema.

Thursday, January 8, 2026

Complement's Gene Therapy for GA Receives FDA Fast-Track Designation

Complement Therapeutics’s CTx001, an investigational gene therapy that targets complement pathways in geographic atrophy, will be evaluated in a phase 1/2 trial in 2026.

Tuesday, January 6, 2026

FDA Clears IND for GenEditBio’s GEB-101 in TGFBI Corneal Dystrophy

The phase 1/2 CLARITY trial will collect initial data on the safety, tolerability, and efficacy of GEB-101 in corneal dystrophy patients with TGFBI mutation.

Tuesday, January 6, 2026

FDA Grants Oculis' Privosegtor Breakthrough Drug Designation

The designation is supported by results from the phase 2 ACUITY trial, in which Privosegtor was evaluated in patients with acute optic neuritis.

Friday, January 2, 2026

New International Myopia Guidance Urges Early, Personalized Care

The Digest reflects a global expert consensus on the definitions, risk factors, prevention, and management of myopia in children and young adults. 

Friday, January 2, 2026

FDA Issues CRL for Outlook's Resubmitted ONS-5010 BLA

The FDA indicated that it cannot approve the application in its present form for the treatment of wet age-related macular degeneration.

Friday, January 2, 2026

FDA Approves Lucentis Biosimilar Nufymco

Ranibizumab-leyk (Nufymco) is approved for all Lucentis indications.

Friday, January 2, 2026

Prevent Blindness Takes Part in National Glaucoma Awareness Month With New Webinar 

As part of National Glaucoma Awareness Month in January, Prevent Blindness announced the availability of free educational resources on glaucoma that eyecare professionals can share with their patients.